What are the definitions, initial management steps, and ongoing treatment recommendations for a patient with sepsis or septic shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sepsis and Septic Shock: Comprehensive Management Guide

Definition and Recognition

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, clinically identified by an acute increase in the SOFA score of 2 points or more. 1

  • Septic shock is a subset of sepsis characterized by persistent hypotension requiring vasopressors to maintain MAP ≥65 mmHg and serum lactate >2 mmol/L (>18 mg/dL) despite adequate volume resuscitation 1
  • Use the qSOFA criteria for bedside screening in suspected infection: Glasgow Coma Score ≤14, systolic blood pressure ≤100 mmHg, and respiratory rate ≥22/min 1
  • Sepsis and septic shock are medical emergencies requiring immediate treatment—do not delay resuscitation 1, 2

Initial Resuscitation (First 3 Hours)

Fluid Resuscitation

Administer at least 30 mL/kg of intravenous crystalloid within the first 3 hours of sepsis-induced hypoperfusion, either before or concurrent with vasopressor initiation. 1, 3

  • Balanced crystalloids (lactated Ringer's or Plasma-Lyte) are preferred over normal saline to reduce hyperchloremic metabolic acidosis 3
  • This 30 mL/kg is a minimum target, not a ceiling—most patients will require additional volume 3
  • Continue fluid challenges as long as hemodynamic parameters improve, using dynamic variables (pulse-pressure variation, stroke-volume variation, passive leg raise) or static signs (MAP, heart rate, mental status, urine output, skin perfusion) 1, 3
  • Stop fluids when no improvement occurs, signs of fluid overload develop, or hemodynamic parameters stabilize 3

Common Pitfall: Do not delay resuscitation due to concerns about fluid overload in patients with heart failure—the standard 30 mL/kg bolus applies even to those with reduced ejection fraction 4

Albumin Supplementation

  • Add albumin when large volumes of crystalloids (several liters) are required, especially in oncotic deficit or prolonged shock 3, 4

Fluids to Avoid

  • Never use hydroxyethyl starch solutions—they increase mortality and acute kidney injury risk 3, 4
  • Avoid gelatin solutions when crystalloids are available 3

Antimicrobial Therapy

Obtain at least two sets of blood cultures (aerobic and anaerobic) before starting antibiotics, then administer broad-spectrum antimicrobials within the first hour of septic shock recognition. 1, 4

  • Do not delay antibiotics >45 minutes for culture collection 1
  • Reassess the antimicrobial regimen daily to narrow spectrum or discontinue 3
  • Consider procalcitonin levels to guide duration or stop empiric therapy in patients with limited clinical evidence of infection 3

Vasopressor Management

First-Line: Norepinephrine

Initiate norepinephrine as the mandatory first-line vasopressor when hypotension persists after adequate fluid resuscitation, targeting MAP ≥65 mmHg. 1, 5, 3

  • Start at 0.05–0.1 µg/kg/min (≈5–10 µg/min for a 70 kg adult) via central venous access 5
  • Place an arterial catheter for continuous blood pressure monitoring as soon as practical 1, 5
  • For chronic hypertension: Target MAP of 70–85 mmHg to reduce need for renal replacement therapy 5

Why norepinephrine? It reduces 28-day mortality by 11% absolute risk reduction compared to dopamine (NNT=9) and causes 53% fewer supraventricular arrhythmias and 65% fewer ventricular arrhythmias 5

Second-Line: Vasopressin

Add vasopressin at a fixed dose of 0.03 units/min when norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains <65 mmHg. 5

  • Vasopressin must always be added to norepinephrine—never use as monotherapy 5
  • Do not exceed 0.03–0.04 units/min except as salvage therapy—higher doses cause cardiac, digital, and splanchnic ischemia 5
  • Vasopressin preferentially constricts the efferent arteriole, producing higher glomerular filtration and better urine output than norepinephrine alone 5

Third-Line: Epinephrine

Add epinephrine starting at 0.05 µg/kg/min (titrate up to 0.3 µg/kg/min) when MAP cannot be achieved with norepinephrine plus vasopressin. 5

  • For a 70 kg patient, maximum dose is 21 µg/min 5
  • Epinephrine causes transient lactic acidosis through β₂-adrenergic stimulation, interfering with lactate clearance as a resuscitation endpoint 5

Inotropic Support: Dobutamine

Add dobutamine 2.5–20 µg/kg/min when MAP is adequate (≥65 mmHg) but signs of tissue hypoperfusion persist, particularly with myocardial dysfunction. 5, 4

  • Indications: elevated lactate, low urine output, altered mental status, cold extremities, or documented low cardiac output 5
  • Discontinue dobutamine when cardiac output is adequate or elevated, as it may worsen hypotension through vasodilation and increase arrhythmia risk 5

Agents to Avoid

Dopamine is strongly contraindicated as first-line therapy—it increases absolute mortality by 11% and causes significantly more arrhythmias than norepinephrine. 5

  • Reserve dopamine only for highly selected patients with bradycardia and low arrhythmia risk 5
  • Low-dose dopamine for renal protection is ineffective (Grade 1A recommendation against use) 5, 3

Phenylephrine is not recommended except in three specific situations: (1) norepinephrine-induced serious arrhythmias, (2) documented high cardiac output with persistent hypotension, or (3) salvage therapy when all other agents have failed 5


Hemodynamic Monitoring and Targets

Blood Pressure Targets

  • Initial MAP target: ≥65 mmHg for most patients 1, 5
  • Restoring MAP to ≥65 mmHg re-establishes renal perfusion pressure above the autoregulatory threshold 5
  • Higher MAP targets (85 mmHg) do not improve renal function, urine output, or lactate clearance in most patients and show no mortality benefit (34% vs 36.6% at 28 days) 5

Tissue Perfusion Markers (Assess Every 2–4 Hours)

Monitor beyond MAP—assess tissue perfusion using lactate clearance, urine output ≥0.5 mL/kg/h, mental status, skin perfusion, and capillary refill. 5, 3

  • Obtain baseline lactate and repeat within 6 hours if elevated; aim for normalization 5, 3
  • Target urine output ≥0.5 mL/kg/h as primary bedside indicator of renal perfusion 5
  • Perform bedside echocardiography to assess cardiac output, ventricular function, and filling pressures—this distinguishes vasodilatory shock (high CO, low SVR) from cardiogenic shock (low CO, high SVR) 5

Dynamic vs. Static Variables

  • Prefer dynamic variables (pulse-pressure variation, stroke-volume variation) over static pressures (CVP) to predict fluid responsiveness 1, 3
  • CVP alone is unreliable for predicting fluid responsiveness, particularly in the 8–12 mmHg range 3

Source Control

Rapidly identify or exclude an anatomic source requiring emergent control and intervene as soon as feasible, ideally within 12 hours. 3

  • Prefer the least physiologically invasive effective intervention (e.g., percutaneous drainage rather than open surgery) 3
  • Promptly remove intravascular access devices that may be the infection source after establishing alternative access 3

Adjunctive Therapies for Refractory Shock

Corticosteroids

Administer hydrocortisone 200 mg/day IV for shock reversal if hypotension remains refractory to vasopressors after at least 4 hours of high-dose therapy. 5, 2

Angiotensin II

  • In profound hypotension unresponsive to standard catecholamines, Angiotensin II can achieve rapid resuscitation by increasing systemic vascular resistance while preserving cardiac output 5

Practical Titration Algorithm

  1. After initial 30 mL/kg crystalloid bolus, if MAP <65 mmHg → start norepinephrine at 0.05–0.1 µg/kg/min 5
  2. Titrate norepinephrine to keep MAP ≥65 mmHg (or 70–85 mmHg in chronic hypertension) 5
  3. When norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains <65 mmHg → add vasopressin 0.03 units/min (fixed dose) 5
  4. If MAP still inadequate → add epinephrine starting at 0.05 µg/kg/min, titrating up to 0.3 µg/kg/min 5
  5. If MAP adequate but hypoperfusion persists → add dobutamine 2.5–20 µg/kg/min to improve cardiac output 5
  6. If refractory after ≥4 hours → add hydrocortisone 200 mg/day IV 5

Special Populations

Patients with Heart Failure (Reduced Ejection Fraction)

  • Apply the standard 30 mL/kg crystalloid bolus even in chronic systolic heart failure (EF <40%)—withholding fluids is not evidence-based 4
  • Norepinephrine has the most favorable cardiac safety profile in heart-failure patients 4
  • Dobutamine is indicated when myocardial dysfunction with low cardiac output persists despite adequate MAP 4

Patients with Chronic Hypertension

  • Target MAP 70–85 mmHg instead of 65 mmHg to lower incidence of renal replacement therapy 5

Critical Pitfalls to Avoid

  • Do not delay vasopressors while pursuing aggressive fluid resuscitation in severe hypotension—early vasopressor use is appropriate when diastolic BP is critically low 5
  • Do not rely solely on MAP numbers—tissue perfusion markers are equally critical for safe management 5
  • Do not use dopamine for renal protection—it provides no benefit and is strongly contraindicated 5, 3
  • Do not exceed vasopressin 0.03–0.04 units/min—higher doses cause end-organ ischemia without hemodynamic benefit 5
  • Do not use phenylephrine as first-line therapy—it may raise BP on the monitor while worsening tissue perfusion 5
  • Do not adopt a "maintenance-fluid" mindset—active, repeated resuscitation guided by hemodynamic response is required 3

Monitoring and Reassessment

  • Continuous assessment should include heart rate, arterial pressure, respiratory rate, oxygen saturation, mental status, urine output, peripheral perfusion, and lactate clearance 3
  • Frequent reassessment is essential—shock management relies on dynamic response rather than fixed protocols 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Emergency medicine updates: Management of sepsis and septic shock.

The American journal of emergency medicine, 2025

Guideline

Fluid Resuscitation and Hemodynamic Management in Shock

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Sepsis Management in Patients with Reduced‑Ejection‑Fraction Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Vasopressor Management in Septic Shock

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.